Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02428712 2025-07-29

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Phase 1/2 Completed

113 enrolled

Other solid neoplasm

Advanced Unresectable Solid Tumors

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT04393298 2025-05-29

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Phase 1/2 Completed

93 enrolled 28 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04914286 2025-05-14

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Phase 1/2 Completed

148 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05052268 2025-05-07

XTX202 in Patients With Advanced Solid Tumors

Phase 1/2 Completed

95 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05830539 2025-05-02

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Phase 1/2 Completed

68 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT02649829 2025-04-29

MESODEC

Phase 1/2 Completed

28 enrolled

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Wilms Tumor

NCT02913313 2025-04-20

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Phase 1/2 Completed

101 enrolled 34 charts

Other solid neoplasm

Broad Solid Tumor

NCT03523351 2025-04-20

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

Phase 1/2 Completed

78 enrolled 10 charts

Other solid neoplasm

Metastatic Solid Tumors of Metastatic Disease

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

58 enrolled

Other solid neoplasmThoracic

Solid Tumor

NCT03903705 2025-04-06

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Phase 1/2 Completed

348 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04597541 2025-03-10

A Study of AK112 for Advanced Solid Tumors

Phase 1/2 Completed

59 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT05188664 2025-02-17

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Phase 1/2 Completed

20 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03593226 2025-02-14

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Phase 1/2 Completed

38 enrolled 13 charts

Other solid neoplasm

Superficial, Palpable, Unresectable/Metastatic Solid Tumour

NCT02240238 2025-01-22

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

Phase 1/2 Completed

119 enrolled 24 charts

Other solid neoplasm

Solid Tumors

NCT04622774 2025-01-15

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

Phase 1/2 Completed

56 enrolled 21 charts

Other solid neoplasm

Advanced Solid Tumor

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

1,163 enrolled 33 charts 2 FDA

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Phase 1/2 Completed

40 enrolled 16 charts

Other solid neoplasm

Solid Tumor, Adult

NCT01291420 2024-12-09

Dendritic Cell Vaccination for Patients with Solid Tumors

Phase 1/2 Completed

48 enrolled

BreastCNSGastrointestinalGenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Renal Cell, Glioblastoma, Sarcoma, Colorectal Neoplasms

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1/2 Completed

300 enrolled 23 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04645069 2024-08-14

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Phase 1/2 Completed

58 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT04121442 2024-08-06

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Phase 1/2 Completed

15 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT01283945 2024-07-25

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Phase 1/2 Completed

134 enrolled

Other solid neoplasm

Solid Tumors

NCT04856774 2024-06-27

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Phase 1/2 Completed

81 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05905614 2024-06-17

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

29 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04001075 2024-04-15

Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors

Phase 1/2 Completed

32 enrolled

Other solid neoplasm

Advanced Solid Tumord

Clinical Trials

VASTUS

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

MK-1200-002

Short Neoadjuvant Hemithoracic IMRT for MPM

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.

EVICTION-2

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

RELATIVITY 059

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours

TRuST

TRESR

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Study of LM-302 in Patients With Advance Solid Tumors

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

XTX202 in Patients With Advanced Solid Tumors

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

MESODEC

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

A Study of AK112 for Advanced Solid Tumors

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Dendritic Cell Vaccination for Patients with Solid Tumors

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors